FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biocon's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0 Mil. Biocon's Revenue for the
three
months ended in Mar. 2026 was ₹44,843 Mil. Therefore, Biocon's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Biocon's FCF Margin % or its related term are showing as below:
NSE:BIOCON'
s FCF Margin % Range Over the Past 10 Years
Min: -9.32 Med: -4.72 Max: 11.41
Current: 0.49
During the past 13 years, the highest FCF Margin % of Biocon was 11.41%. The lowest was -9.32%. And the median was -4.72%.
NSE:BIOCON's FCF Margin % is ranked better than 74.87% of 955
companies
in the Biotechnology industry
Industry Median: -84.65
vs NSE:BIOCON: 0.49
Biocon FCF Margin % Related Terms
Biocon FCF Margin % Historical Data
* Premium members only.
The historical data trend for Biocon's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BIOCON vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Biocon's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocon FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocon's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biocon's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocon (NSE:BIOCON) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biocon and its competitors. According to the industry distribution chart, Biocon ranks #240 out of 955 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Biocon's FCF Margin % too high?
Biocon's current FCF Margin % is 0.00%. Based on the distribution chart, Biocon ranks #240 out of 955 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocon has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #240 out of 955 companies for FCF Margin %. This puts Biocon in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biocon and its competitors. Biocon's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.27, compared to a current price of ₹418.60 — trading 23.4% above its estimated fair value. The current FCF Margin % is 0.00%. Biocon's overall GF Score™ is 85/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹418.60 is trading 23.4% above its estimated GF Value™ of ₹339.27.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
FCF Margin %: 0.00%
GF Value™: ₹339.27 vs. price of ₹418.60 (23.4% above fair value)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
85GF Score
Get the complete analysis for NSE:BIOCON
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
